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Abstract 10 
Antibiotics target essential cellular functions but bacteria can become resistant by acquiring 11 
either exogenous resistance genes or chromosomal mutations. Resistance mutations 12 
typically occur in genes encoding essential functions, which causes resistance mutations to 13 
be generally detrimental in the absence of drugs. However, bacteria can reduce this 14 
handicap by acquiring additional mutations, known as compensatory mutations. Genetic 15 
interactions (epistasis) either with the background or between resistances (in multi-resistant 16 
bacteria) dramatically affect the fitness cost of antibiotic resistance and its compensation, 17 
therefore shaping dissemination of antibiotic resistance mutations. This review summarizes 18 
current knowledge on the evolutionary mechanisms influencing maintenance of resistance 19 
mediated by chromosomal mutations, focusing on their fitness cost, compensatory evolution 20 
and epistasis and the effect of the environment on these processes.  21 
  22 
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The threat of bacterial antibiotic resistance 23 
The introduction of antibiotics represented one of the most important medical interventions 24 
in the history of global health resulting in a dramatic reduction in human morbidity and 25 
mortality caused by bacterial infections. However, the intensive use of antibiotics has 26 
accelerated the dissemination of bacteria that evolved to endure these drugs through the 27 
acquisition of genes or chromosomal mutations that confer resistance [1,2]. Antibiotic 28 
resistance (AR) is widespread in clinical [3,4] and environmental settings [5,6], providing a 29 
reservoir that can further spread by horizontal gene transfer. AR is a serious and growing 30 
challenge in the treatment of infectious disease 31 
(http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-32 
bacteria/en/), with single and multidrug resistant clones of major pathogens circulating at 33 
frequencies above those expected by a balance between the stochastic emergence of 34 
resistance by mutation and a purge of deleterious mutations (in the absence of antibiotic) by 35 
natural selection [7]. The dissemination of multidrug resistant bacteria is unfortunate 36 
because these clones are harder to treat and those harbouring mobile resistance elements 37 
(MREs) are able to spread resistance more quickly. Antibiotic resistant infections world-wide 38 
are estimated to potentially cause millions of deaths by 2050 (https://amr-review.org/) and 39 
already inflict a major economic toll [8]. Beyond complex demographic processes, the 40 
emergence and dissemination of AR in bacterial populations depends on key evolutionary 41 
parameters, such as (i) the rate at which bacteria acquire resistance, (ii) the selective 42 
pressures for and against resistant bacteria (see Glossary), and (iii) the rate and effects of 43 
mutations compensating for potential costs of resistance (see Glossary) [9]. These factors 44 
have been shown to be influenced by both the genetic background and the environment in 45 
which resistant bacteria grow [10], underlining the necessity of  experimental studies and 46 
quantitative analysis of these rates and processes in vivo, e.g. in ecological contexts related 47 
to infections, and in nature, e.g. in microcosms mimicking natural habitats. Such studies are 48 
vital to preserve the effectiveness of antibiotics and reduce the frequency of resistance in 49 
bacterial populations. Here we summarize up-to-date knowledge on the evolutionary 50 
mechanisms influencing maintenance of resistance mediated by chromosomal mutations. In 51 
particular, we will focus on fitness cost of AR, compensatory evolution, epistasis and 52 




Emergence of bacterial antibiotic resistance 55 
The rate of appearance of antibiotic-resistant bacteria is determined by the combined rates 56 
of de novo mutation (U) and horizontal gene transfer (HGT) of mobile genetic elements 57 
carrying resistance (MRE, see Box 1). While acquisition of new DNA requires specific 58 
ecological contexts (i.e.: the presence of donor bacteria), adaptive mutations (potentially 59 
including resistance mutations) are continuously generated at rates that can be as high as 60 
~10-5 per cell per generation [11–13]. Furthermore, mutations leading to genomic 61 
rearrangements (insertions, deletions, duplications, inversions) occur at an even higher rate 62 
(10-3-10-5 per cell per generation) which can accelerate the rate of acquiring AR [14,15]. The 63 
rate of the emergence of AR mutants is affected by physiology, genetics, antibiotic-64 
bacterium interactions (e.g.: antibiotic itself can affect mutation rate [16] or different 65 
resistance mutations can be selected at different antibiotic doses [17]), and the current and 66 
past environment to which bacteria have been exposed (e.g.: bacteria grown at high 67 
temperature can acquire rpoB mutations conferring rifampicin resistance [18]), together 68 
with the physical structure of the selective medium [12]. 69 
It is important to note that antibiotic stress itself can impact the general value of U. Indeed, 70 
a growing body of evidence suggests that sub lethal concentrations of several antibiotics can 71 
boost resistance emergence via increasing the rate and frequency of HGT, recombination, 72 
and mutagenesis [19]. Furthermore, bacteria can acquire mutations that increase their 73 
genome-wide U typically 10 to 1000-fold – known as “mutators”. In fact, it has been long 74 
known that recurrent pressure of antibiotics selects for mutator clones due to their 75 
increased ability to produce the rare mutations that can rescue bacterial populations from 76 
such high selective pressures [20]. Mutators are also known to exhibit increased ability for 77 
recombination [21]. In samples of natural isolates of Escherichia coli,  clones with 78 
intermediate mutator phenotypes have been found to carry significantly more AR mutations 79 
[22]. 80 
Hence, bacteria have an enormous potential for adaptation with access to a large supply of 81 
mutations and exogenous genetic material that could explain why AR evolves remarkably 82 
quickly both in laboratory and clinical environments [23,24]. 83 
However, in the context of infection, bacterial population sizes within hosts are high enough 84 
(above 1010 in certain contexts) to already include pre-existing resistant mutants [9]. In such 85 
a large bacterial population, and considering a base-substitution mutation rate of around 10-86 
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9-10-10 per nucleotide site per generation [25], it is possible that all viable mutations, 87 
including resistance mutations, would already exist in the population. Thus, the current 88 
estimates of mutation rates and the large population sizes suggest that U may have a limited 89 
influence on the emergence of resistances. On the other hand, population genetic theory 90 
has shown that i) if a population is facing antibiotic pressure once a resistance mutation 91 
arises, its chances of not getting lost and spreading depend on its beneficial fitness effect (its 92 
selection coefficient); ii) if a population does not experience antibiotic pressure, the 93 
resistance mutation is expected to attain a frequency reflecting the balance between the 94 
rate of production of the mutants (proportional to U) and the rate of elimination by natural 95 
selection (the deleterious fitness effect resulting from a cost of resistance) or by genetic drift 96 
(random changes in the frequency of resistant mutants in a population). In light of the 97 
unavoidable escape of recurrent mutations associated with cell division, restriction of 98 
resistance relies on the power of purifying selection acting on the costs that resistance 99 
mutations might cause (Figure 1) [26,27]. 100 
 101 
Fitness costs associated with antibiotic resistance 102 
From in vitro studies, the acquisition of resistance is often associated with fitness costs in the 103 
absence of antibiotics [1,4,28]. Deleterious effects are thought to originate either from the 104 
cost of maintaining resistance carrying plasmids (see Box 1) [29–36] or from the pleiotropic 105 
effect of chromosomal resistance mutations [1,4,37]. In the latter case, costs are often 106 
associated with the fact that resistance mutations map onto genes encoding essential 107 
cellular functions (targeted by antibiotics), such as transcription, translation or cell wall 108 
biogenesis. 109 
The existence of a fitness cost caused by AR predicts that the fitter susceptible strain should 110 
outcompete the resistant strains over time (Figure 1) [28]. This is in agreement with the 111 
observed decrease of antimicrobial resistance in clinical settings when the use of certain 112 
antimicrobials is halted [38–41]. However, costs are not always found to occur [28]. For 113 
example mutations causing streptomycin and/or rifampicin resistance could confer survival 114 
benefits to bacteria engulfed by macrophages [42,43]; mutations conferring rifampicin 115 
resistance could spread to high frequencies in bacterial populations growing under limited 116 
resources [18,44]; mutations conferring carbapenem resistance were found to confer a 117 
competitive fitness advantage to Pseudomonas aeruginosa colonizing the mouse intestine 118 
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and disseminating to the spleen [45]; carbapenem and fosfomycin resistance mutants can 119 
have increased virulence in a murine pneumonia model [46]; and mutations conferring 120 
vancomycin resistance can be selected for as a result of competition between diversified 121 
genotypes of Staphylococcus aureus spontaneously generated from a common ancestral 122 
strain [47].  123 
The examples above also underline the strong influence of the environmental conditions on 124 
the fitness cost of resistances [37,48,49]. However, based on the studies that have been 125 
performed, fitness measurements made in the laboratory settings appear to have clinical 126 
relevance since they agree with epidemiological studies of the prevalence of resistance 127 
alleles in clinical isolates [50–52]. 128 
 129 
Benefits and costs in the presence of antibiotics 130 
While fitness effects of resistance mutations show a strong genotype-by-environment 131 
interaction [49] in the absence of antibiotics, their benefits are less dependent on the 132 
environment complexity if high antibiotic pressure is applied. This permits the use of 133 
experimental evolution in the lab to anticipate the spectrum of beneficial mutations causing 134 
resistance to high antibiotic doses. Indeed many of the resistance mutations in clinical 135 
isolates can be evolved in the lab, under the appropriate selective pressure [53].  136 
The acquired level of resistance to the antibiotic is experimentally measured through the 137 
minimal inhibitory concentration (MIC). The level of resistance can vary extensively 138 
depending on the resistance mechanism and the conditions under which resistance is 139 
measured. For instance, if the resistance mechanism affects monotonically the growth with 140 
the drug concentration, then the relative fitness of an antibiotic-resistant bacterium might 141 
vary extensively depending on antibiotic concentration [9,54]. While it is clear that the high 142 
concentrations of antibiotics used therapeutically can select for resistant mutants, it has 143 
been shown both in E. coli and Salmonella enterica that concentrations of tetracyclines, 144 
quinolones, and aminoglycosides hundreds-fold below the MIC of susceptible bacteria can 145 
select for resistant bacteria [3,55]. Importantly, it is not currently known if measurements of 146 
resistance levels in the laboratory, typically performed in conditions far from natural, can be 147 
extrapolated to resistance levels of bacteria in a host. In a host, inter-species ecological 148 
interactions are likely to occur that are inexistent in most in vitro studies, some of which 149 
could buffer the antibiotic pressure experienced by a particular bacteria [56,57]. 150 
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An interesting environmental effect mediated by the presence of antibiotics on the fitness of 151 
resistant strains relates to the potential biological activities in degrading antibiotics. For 152 
instance, certain products of the physicochemical degradation of tetracycline are more 153 
harmful for resistant than for sensitive E. coli, causing the competitive advantage conferred 154 
by the resistance to eventually reverse and become disadvantageous [58]. 155 
Troublingly, certain mechanisms confer resistance to antibiotics at unknown fitness costs. 156 
For instance, a set of mutations in genes encoding ribosomal components in Mycobacterium 157 
smegmatis confer resistance to diverse antibiotics not related structurally or mechanistically, 158 
by causing extensive transcriptomic and proteomic changes, affecting proteins known to 159 
impact AR [59]. Furthermore, bacterial populations can collectively survive antibiotic 160 
treatments lethal to individual cells via diverse mechanisms, such as production of resistance 161 
enzymes, bistable growth inhibition mediated by antibiotic titration, swarming or 162 
interactions between different bacterial subpopulations. These strategies allow bacterial 163 
populations to survive upon antibiotic treatment and provide a time window for the 164 
acquisition of genetic resistance [60]. 165 
 166 
Compensation of the fitness costs 167 
Despite the importance of the fitness costs in predicting the dissemination of AR mutations, 168 
there are additional factors that significantly affect the evolutionary path of AR. The rapid 169 
acquisition of compensatory mutations by resistant clones is key to prevent them from being 170 
outcompeted by sensitive bacteria, as widely described for the cost of single resistance both 171 
in clinical [61,62] and laboratory conditions [63–67]. Compensation can occur either by 172 
losing the original resistance mutation which is causing the fitness decrease – a process 173 
known as reversion (Box 2, recently discussed in [68]) - or by acquiring additional mutations 174 
which counteract the cost. Compensatory mutations generally affect genes encoding 175 
proteins involved in cellular machinery functionally related to those affected by the original 176 
mutation [69]. 177 
The dynamics of compensatory adaptation depends on population size, bottlenecks [63], 178 
mutation rate [70], and the distribution of fitness effects of compensatory mutations, which 179 
depends on the genetic background due to genetic interactions  [71,72]. For instance, in the 180 
simplest case of a single resistance mutation, it has been shown that compensation is 181 
typically faster when the fitness cost of the resistance mutation is higher, leading to the 182 
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prediction that clones carrying more costly resistance mutations have higher adaptive 183 
potential. This faster adaptation is likely driven by the acquisition of compensatory 184 
mutations with larger effects on these backgrounds [73]. In the more complex case, where a 185 
population carries genetic variation for resistance mutations, the different clones will have 186 
different distributions of compensatory mutations and high competition between clones 187 
with different fitness - clonal interference – may result in the maintenance of costly 188 
resistance alleles over long periods of time. For example, a study using experimental 189 
evolution with resistant E. coli clones observed coexistence between costly rifampicin and 190 
less costly streptomycin resistance mutations during hundreds of generations [71]. This type 191 
of study exposes the complexity of the fitness landscape and the evolutionary dynamics, 192 
which impacts predictions about extinction of high cost resistances. 193 
Even though compensation of resistant bacteria is often studied in the absence of antibiotic 194 
[65–67,70], it can also occur in the presence of antibiotics. For instance, mutations that 195 
decreased both the cost of resistance to fluoroquinolone and the susceptibility to the 196 
antibiotic have been described [74,75]. The few studies that have compared bacterial 197 
compensation in the absence versus presence of antimicrobial selection pressure [64,76] 198 
indicate that both the targets of compensation in the presence of antibiotic and their fitness 199 
effects can be different from the ones in the absence of the drug. For instance, mupirocin 200 
resistant mutants, carrying compensatory mutations acquired in absence of the drug, have 201 
increased fitness only in this environment and not when the antibiotic is present [76]. 202 
The effects of the presence or absence of antibiotics on compensatory evolution of resistant 203 
bacteria become particularly relevant in light of the current discussion on the appropriate 204 
duration of antibiotic treatments [77]. Although for certain infections there is strong 205 
evidence on what is the optimal duration of an antibiotic course, this is unknown for many 206 
other infections [78]. In case of long treatments (Fig. 1B top panel), resistant mutants are 207 
able to reach large population sizes, which favours compensation during the antibiotic 208 
treatment. Thus, compensation in presence of antibiotic becomes more significant, as the 209 
effects of compensatory mutations acquired during the antibiotic treatment on bacterial 210 
fitness in an antibiotic-free environment will likely determine whether compensated 211 
resistant bacteria can be outcompeted or not. Conversely, in case of short treatments (Fig. 212 
1B bottom panel), resistant mutants are unlikely to take over the entire population, making 213 
compensation during treatment much more difficult. In these cases, compensatory evolution 214 
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in absence of antibiotics constitutes a better framework for predicting the evolutionary fate 215 
of resistant bacteria. Efforts to elucidate the optimal duration of antibiotic treatments for 216 
each infection are therefore essential to determine the most relevant environment to study 217 
compensatory evolution and, subsequently, elaborate predictions on the evolutionary 218 
trajectories of resistant pathogens [9]. 219 
Another example of environmental effects on compensation with relevant clinical 220 
implications was the observed selection of different compensatory mutations depending on 221 
whether the resistant bacteria evolved in mice or in laboratory conditions, indicating that 222 
compensatory evolution can take different trajectories within and outside a host [67]. 223 
Indeed, the clinical and epidemiological importance of compensation remains poorly 224 
understood [4,79–81]. 225 
 226 
Epistatic effects on antibiotic resistance 227 
Epistasis occurs when the effect of a mutation depends on the genetic background where it 228 
arises. It is has been shown that the same AR mutation can have different effects if it occurs 229 
in different genomes [82–84]. For example, strains harbouring identical rifampicin resistance 230 
mutations but belonging to different lineages of Mycobacterium tuberculosis showed 231 
different levels of fitness cost [79]. Likewise, the available data suggests that the bacterial 232 
genetic background can also influence the fitness of bacteria with MRE [36,85,86]. Epistasis 233 
can have profound implications for the spread of bacterial AR [48,87–89]. In the simplest 234 
case, epistasis can be quantified between two loci - pair-wise epistasis- and it can be positive 235 
or negative (see Figure 2A for details). 236 
Positive (negative) epistasis occurs when the fitness of a clone carrying mutations at the two 237 
loci is higher (lower) than expected given the effects in fitness of each of the single mutants. 238 
Furthermore, an important form of interaction – sign epistasis - can occur if the sign of the 239 
effect changes from deleterious to beneficial (or vice-versa) in the double mutant [90]. Non-240 
reciprocal sign epistasis occurs when the double mutant fitness is higher (or lower) than one 241 
of the single mutants, whereas reciprocal sign epistasis occurs when the double mutant 242 
fitness is higher (or lower) than both single mutants (Figure 2A). The strength and type of 243 
epistasis is also known to depend on the environmental context, as expected given that the 244 
fitness effects of resistance differ with the growth media [49]. 245 
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Epistasis strongly affects the dissemination of AR because it can greatly influence the 246 
dynamics and repeatability of evolution at numerous stages [88,91–95]. For instance, during 247 
a constant antibiotic treatment a phenomenon called diminishing returns epistasis can 248 
occur, where the beneficial effect of the resistance mutations decreases as they sequentially 249 
accumulate, limiting the subsequent evolution [84]. 250 
Epistasis has a decisive role during compensation of costly AR mutations in the absence of 251 
drugs. Most compensatory mutations are deleterious or neutral in the sensitive background, 252 
but advantageous in the resistant background [72]. As a consequence, the persistence of 253 
resistance mutations upon compensation is promoted because reversions will strongly be 254 
selected against. A bacterial population enriched with resistant mutants carrying 255 
compensatory mutations can readily acquire a second resistance, either by accumulating 256 
chromosomal mutations selected for in the presence of a new antibiotic, and/or by acquiring 257 
plasmid-borne resistant elements (Box 1), leading to multidrug resistant strains [80,96]. 258 
Importantly in the context of multiple-resistance, different resistance mutations can also 259 
interact epistatically. Studies in E. coli, P. aeruginosa, M. tuberculosis, Salmonella enterica 260 
and Streptococcus pneumoniae found many instances of positive epistasis, with the 261 
observed cumulative fitness cost of carrying multiple drug resistance-conferring mutations 262 
below the expected sum of the fitness costs associated with each individual mutation 263 
[48,87,97–99]. Positive epistasis between chromosomal resistance mutations and MRE or 264 
between different MRE has also been observed (Box 1). Pervasive positive epistasis was 265 
found not only between costly resistance mutations but also when combining costless 266 
rifampicin resistance alleles with costly streptomycin resistance alleles [48]. Moreover, 267 
double resistant clones were also shown to exhibit sign epistasis [87,90], with the 268 
implication that in the absence of antibiotics the acquisition of further resistance mutations 269 
(or eventually plasmids) can increase the fitness of an initially single resistant strain, 270 
resulting in reduced probability of reverting  resistance by halting drug use. 271 
Fortunately, although not as commonly as desired, examples of pairs of resistance mutations 272 
which interact negatively have also been found [87]. Knowledge of these negative epistatic 273 
interactions between resistance mutations is important and can be clinically explored to 274 
slow down the evolution of multi-resistance by using specific combinations of antibiotics. If, 275 
for a given pair of drugs, negative epistasis is expected to dominate the landscape of 276 
potential emerging resistance mutations, then the few double resistant genotypes that 277 
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would survive the treatment would have highly reduced fitness, and be outcompeted by 278 
single resistant and/or susceptible genotypes once the antibiotic treatment is completed. 279 
Importantly, resistance to one drug might also increase susceptibility to another drug – a 280 
phenomenon called collateral sensitivity [100] – which constitutes another relevant 281 
interaction that can be used to combat resistant strains. 282 
Notably, compensatory evolution of multi-resistant strains can also be affected by epistasis. 283 
Although this topic remains poorly explored, the common observation of epistasis between 284 
resistance mutations implies that compensation of multiple-resistance bacteria can 285 
significantly differ from that of single resistant strains (Figure 2B). In the case of positive 286 
epistasis one could expect that the process of compensation would entail less compensatory 287 
targets than those involved in the compensation for costs of each single resistance. This 288 
should be especially strong under sign epistasis, where multi-resistant clones have higher 289 
fitness than some of the single resistant clones. On the contrary, negative epistasis should 290 
result in a higher number of compensatory targets, as mutations specifically compensating 291 
for the negative epistasis could be expected. A recent study [72] showed that this can indeed 292 
occur. By following the compensatory process of a streptomycin and rifampicin double-293 
resistant E. coli and comparing it with that of single-resistant clones, the study unveiled 294 
mutations in gene targets that only compensate for double resistance, e.g a specific amino 295 
acid change in rpoC and a mutation causing increased expression of nusG. These mutations 296 
were neutral or deleterious in sensitive or single resistant backgrounds, demonstrating their 297 
compensatory nature solely under double-resistance. The study also showed that the 298 
compensatory effect of the mutations disappeared in an environment where the epistatic 299 
interaction between resistance alleles was absent, consistent with the hypothesis that these 300 
mutations were specifically compensating for the epistatic interaction between the ARs [72]. 301 
The detection of compensatory targets for epistasis can lead to the identification of proteins 302 
involved in multiple essential processes. These proteins are potential targets for the 303 
development of new antimicrobials, since their functional inhibition could strongly affect 304 
bacterial fitness, furthermore limiting the rise of resistance mutations because these would 305 
be particularly deleterious in these conditions. 306 
Epistasis can also occur at the intragenic level. There is plentiful evidence for sign epistasis 307 
during the evolution in β-lactamases towards high levels of AR [88,91,101,102]. Remarkably, 308 
sign epistasis was shown to limit the number of evolutionary paths available to evolve 309 
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increased resistance. For instance, during the evolution of classical β-lactamases into 310 
extended-spectrum β-lactamases (ESBL), pervasive sign epistasis between mutations was 311 
observed, where many mutations, individually leading to increased ability to degrade 312 
cephalosporins, showed decreased MIC when combined [88]. In the system studied only 18 313 
out of the 120 possible evolutionary pathways continuously increased the MIC. 314 
A likely reason for such frequent epistasis is that mutations are often pleiotropic, 315 
simultaneously affecting multiple phenotypes [91]. Pleiotropy is a key assumption in classical 316 
models of adaptation to novel environments such as Fisher’s geometric model (FGM, see 317 
Box 3), which describes the relationship between multiple phenotypic traits and fitness, and 318 
predicts complex patterns of epistasis [103–105].  319 
A common form of pleiotropy within proteins is the simultaneous effects of mutations on 320 
enzyme activity and stability [101,106,107]. For instance, on the β-lactamase TEM-1, 321 
mutations which increased activity against cephalosporin antibiotics lost thermodynamic 322 
stability. However, a second mutation which is neutral or deleterious by itself stabilizes the 323 
proteins carrying an activity-increasing mutation, another example of sign epistasis [106]. 324 
Interestingly, it has also been shown that the deleterious effect of a fraction of the 325 
destabilizing mutations can be buffered by interacting with bacterial chaperones [108,109], 326 
yet another source of epistasis with unexplored consequences for AR. 327 
There are very few studies investigating if epistasis occurs frequently during the evolution of 328 
multidrug resistant strains in clinical settings. Nevertheless, in clinical isolates of multidrug 329 
resistant M. tuberculosis, resistant to both rifampicin and ofloxacin, many carried a 330 
particular mutation known to confer ofloxacin resistance in the gyrA gene. This mutation has 331 
been shown in laboratory settings to have positive epistasis with several rpoB mutations 332 
(which confer rifampicin resistance) [99]. Clearly, further epidemiological studies are 333 
required to understand to which extent epistasis is relevant in clinical contexts. 334 
 335 
Concluding remarks 336 
Due to the high evolutionary potential of bacteria, the initial golden age of antibiotics to 337 
treat bacterial infections is quickly turning to a bronze age. In vitro and in vivo experimental 338 
evolution studies are fundamental to anticipate the evolutionary paths likely to be taken by 339 
potential pathogens upon exposure to drugs and to educate the society to the reality of 340 
microbial rapid evolutionary change. Currently, most studies of epistasis on AR rely on 341 
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observations between two resistance alleles or in between an AR mutation and the genetic 342 
background where it appears. The unfortunate reality of high frequency of multiple-343 
resistance (e.g. clones carrying three and more resistances are becoming common), 344 
however, demands an understanding of higher order epistasis. This is a challenging task, but 345 
one that is urgently necessary. Profiting from the rapid evolution of bacteria in the lab, both 346 
to acquire multiple resistance and to compensate for resistance costs on fitness, 347 
experimental evolution studies focusing on key ecological and evolutionary factors (such as 348 
treatment duration, specific combinations of antibiotics and epistasis) may allow to more 349 
effectively manipulate and reduce the danger of multiple resistance.  350 
It is also important to remember that fitness costs, compensation and epistatic effects are 351 
strongly environmental-dependent. Thus, further studies of competition, colonization, 352 
compensation and transmission using animal models are required (see Outstanding 353 
Questions). Such in vivo studies are likely essential to identify antibiotic targets that can 354 
hardly be compensated. Furthermore new surveys are required to quantify how pervasive 355 
epistasis is in clinical populations of pathogens. This knowledge would provide a theoretical 356 
framework for the development of novel antimicrobial strategies and therapeutic agents 357 
aiming at minimizing the evolution of multidrug resistance. 358 
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 367 
BOX 1 – Antibiotic resistance conferred by mobile genetic elements 368 
Mobile genetic elements carrying resistances (MRE) play a key role in the spread of AR, since 369 
they can disseminate in bacterial populations by horizontal gene transfer (HGT) [27]. MRE 370 
typically carry genes encoding functions that counteract the action of antibiotics by either 371 
enzymatic inactivation [110], efflux [111], synthesis of alternative enzymes to native targets 372 
[112] or target protection [113,114]. Three principal evolutionary mechanisms of HGT are 373 
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conjugation [115], transduction [116], and natural transformation [117], although alternative 374 
mechanisms have also been described [118]. 375 
Conjugation and transduction frequencies can be much higher in vivo than in vitro [29,119–376 
122]. For example, in the context of the gut microbiota it was found that inflammation could 377 
greatly increase the rates of plasmid and bacteriophage transfer between Salmonella strains. 378 
Regarding natural transformation its prevalence is still not well quantified. Since the gut 379 
microbiota is a reservoir of AR genes [123,124], the HGT of MRE is likely frequent in the gut 380 
[125]. Among MRE, plasmids are probably the most clinically relevant [27]. The mechanisms 381 
underlying the effects of plasmid carriage on bacterial fitness in the absence of antibiotics 382 
remain poorly understood [52,126–128]. Interestingly, different plasmids cause diverse 383 
effects on bacterial fitness, ranging from large deleterious effects to no cost or even fitness 384 
advantage [52,126,127]. This heterogeneity can originate from plasmid features (size, 385 
resistance range, number of resistances, etc.), interference with the host physiology or 386 
interactions with the environment [129–131]. The fitness cost associated with plasmid 387 
carriage can be counterbalanced by acquiring compensatory mutations, either in the 388 
plasmid, in the bacterial chromosome, or in both [32,132–134]. These mutations often 389 
influence replication and transmission rates, impacting plasmid dissemination in bacterial 390 
populations [34,135]. Importantly, epistatic interactions between plasmids and 391 
chromosomal loci or other MRE [89,133,136–138] have been observed. Remarkably, these 392 
interactions include epistasis between plasmids and chromosomal resistance mutations 393 
[139], indicating that the acquisition of one resistance can favour or prevent the emergence 394 
of further resistance. Understanding the mechanisms underlying maintenance and 395 
dissemination of MRE in bacterial populations is thus essential to face the challenge of 396 
spreading ARs. 397 
 398 
BOX 2 – Compensation through reversions 399 
A particular case of compensation is reversion, when the adaptive mutation completely 400 
reverts the fitness costs by returning to the original genetic sequence. When reversion 401 
occurs in the presence of antibiotic, revertants are likely lost due to strong selection against 402 
them (alternatively, revertants can also be lost by genetic drift). Thus, reversion is 403 
considered to occur only in the absence of antibiotics and is clinically relevant since the 404 
bacteria re-gain sensitivity. However, compensation by acquiring additional mutations is far 405 
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more likely to occur than genetic reversion, since the range of targets for compensation is 406 
much broader [1]. 407 
Interestingly, phenotypic reversion (phenotypic sensitivity caused by the acquisition of an 408 
additional mutation, but maintaining the original resistance mutation) can also occur. For 409 
instance, mutations in the rpsL gene – encoding a ribosomal protein - confer resistance to 410 
streptomycin but several compensatory mutations occurring in other ribosomal proteins 411 
[140] or in translation elongation factors [141] can phenotypically revert resistance. 412 
More recently, three studies have developed promising strategies to convert resistant 413 
bacteria into phenotypically sensitive to the original antibiotics [142–144]. The first study has 414 
re-sensitized resistant bacteria by treating it with a specifically designed oligonucleotide 415 
which acts as an antisense mRNA translation inhibitor and can be designed to target the 416 
mRNAs encoding resistance genes such as a constituent of the major drug efflux pump [142]. 417 
In the second study, a spiroisoxazoline family of Small Molecules Aborting Resistance 418 
(SMARt) was developed to phenotypically revert acquired resistance of M. tuberculosis to 419 
the prodrug ethionamide by inducing the expression of an alternative bioactivation pathway 420 
[143]. The SMARt molecule fully reversed ethionamide-acquired resistance and efficiently 421 
cleared an ethionamide-resistant infection in mice. In the third study, the assembly of 422 
functional membrane microdomains (structurally and functionally similar to lipid rafts of 423 
eukaryotic cells) of methicillin-resistant S. aureus (MRSA) was targeted and as a result 424 
resistance to penicillin was reverted both in vitro and in vivo [144]. 425 
 426 
Box 3 - Antibiotic resistance in light of Fisher’s model of adaptation 427 
Taking into account that the fitness effects of AR mutations are strongly dependent on the 428 
environment, it is of paramount importance to be able to anticipate the effect of resistance 429 
mutations across environments. Fisher’s geometric model (FGM), which assumes a fitness 430 
landscape with a single peak, is a theoretical framework that allows predictions on the 431 
distribution of fitness effects (DFE) of mutations [145]. Under FGM an environmental change 432 
can be theoretically thought of as a change in the distance to the optimum of a given 433 
population or a change in the position of the optimum itself. FGM assumes that mutations 434 
affect pleiotropically a number of quantitative traits under stabilizing selection and many 435 
antibiotic targets are known to have pleiotropic effects. Maybe that is why this model has 436 
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been effective in describing the fitness effects of antibiotic resistance in the absence [49] 437 
and presence of antibiotic [17]. 438 
For instance, a study [49] using mutations in E. coli conferring resistance to streptomycin, 439 
rifampicin or D-cycloserine found that antibiotic mutation effects in the absence of antibiotic 440 
were well described by a shifted gamma distribution as predicted by FGM, with a shift 441 
parameter (reflecting the distance to the fitness peak) varying across environments. A 442 
somewhat extended FGM was also robust enough to accurately describe the mutational 443 
pattern of AR in E. coli across a gradient of nalidixic acid, a quinolone [17]. The implemented 444 
extensions took into account that: i) only a minor subset of mutations from specific regions 445 
of the genome will affect the ability to resist antibiotics (modularity). This proportion of 446 
resistance mutations seems to sharply decrease with the increase of the antibiotic 447 
concentration, a result with clinical relevance; ii) the effect of a mutation is dependent of the 448 
environmental selective constraints and thus, the same mutation may confer a fitness 449 
increase in one environment and not in others; and iii) different antibiotic concentrations 450 
may either constrain the optimal fitness that populations can reach (changing the height of 451 
the fitness peak) or change the rate of fitness increase with each mutation (changing the 452 
width of the peak). In the future, it will be important to distinguish in between these two 453 
latter processes. 454 
Lastly, FGM also provides a reasonable theoretical framework to predict the dynamics of 455 
compensatory evolution of AR [146]. For instance, FGM predicts that compensatory 456 
mutations should occur at higher rates and cause higher fitness increases in strains where 457 
the costs of AR are larger. 458 
 459 
Glossary 460 
antibiotic resistance - an inheritable ability of microorganisms to grow at high 461 
concentrations of antibiotic (independently of whether it is bacteriostatic or 462 
bactericidal) and irrespective of the duration of treatment. 463 
natural selection - evolutionary process by which the genotypes best phenotypically 464 
adapted to a particular environment in a population, increase in relative frequency 465 
with respect to less adapted organisms over generations. 466 
fitness - a term that refers to the survival and reproductive success of an organism in 467 
an environment. In bacteria relative fitness is measured by competing two genotypes 468 
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(i.e.: resistant versus sensitive) and accounting for the change in frequency over time 469 
(competitive fitness). Fitness of bacteria can also be estimated by measuring 470 
reproductive related traits such as growth rate, carrying capacity or length of lag 471 
phase. 472 
selective pressure – an evolutionary effect exerted by any cause or agent (i.e.: an 473 
antibiotic) that increases or reduces the reproductive success (fitness) of a genotype,  474 
changing its frequency in a population. 475 
cost of resistance – deleterious effect to an organism fitness caused by the presence 476 
of either a chromosomal mutations conferring resistance or mobile genetic elements 477 
carrying resistance. 478 
reversion – genetic reversion occurs when a mutation returns to the original genetic 479 
sequence. Phenotypic reversion of an AR mutation occurs when the resistance 480 
mutation is maintained but the sensitive phenotype is restored. 481 
compensatory mutations – adaptive mutations which reduce the fitness costs 482 
caused by a pre-existing condition, such as the  presence of antibiotic resistance 483 
mutations or MRE. 484 
epistasis - phenomenon where the effect of one mutation is dependent on the 485 





FIGURE LEGENDS 489 
 490 
Figure 1 – Emergence and maintenance of bacterial antibiotic resistance. 491 
(A) Multidrug resistance under natural selection. E. coli can acquire rifampicin (Rif) and 492 
streptomycin (Str) resistance through mutations in the rpoB or rpsL genes, respectively (blue 493 
and purple circles), which allow the bacteria to survive during an antibiotic treatment 494 
(represented by the capsules). After antibiotic treatment, acquisition of resistance is often 495 
associated with fitness costs (red arrows) which can be alleviated (brown arrows) by 496 
compensatory mutations in known gene targets (orange circles). Bacterial population after 497 
rifampicin treatment will be enriched in resistance with compensated costs and, if submitted 498 
to subsequent treatments with other antibiotics (i.e.: streptomycin), may lead to the 499 
development of multiple resistances by the acquisition of mutations. (B) Compensation 500 
under short-term and long-term antibiotic treatments. Use of antibiotics can strongly select 501 
for resistant mutants (a), favouring multiplication of the resistant strain (b). On a long-term 502 
antibiotic treatment (upper panel), competition between resistant strains will increase over 503 
time and compensation to the fitness costs is likely to occur during the treatment (c). In a 504 
short-term antibiotic treatment (bottom panel), compensation during treatment is unlikely 505 
because the advantage of resistance over the susceptible bacteria outweighs the fitness 506 
costs. In both scenarios, once the antibiotic treatment finishes, resistant strains will often 507 
have a fitness costs when competing against the susceptible strain and compensation will 508 
occur (c). Time course of antibiotic treatment results in bacteria with different genetic 509 
backgrounds since they compensate differently for the costs of resistance. Whether this 510 
compensation occurred in presence or absence of antibiotics may strongly affect the fate of 511 
these mutants in competition with the sensitive strain. 512 
 513 
Figure 2 – Genotype-by-genotype-by-environment (GxGxE) interactions. 514 
(A) Epistasis between costly resistances. Epistasis can be negative, whereby the fitness of 515 
the double resistance is lower than expected, or positive, whereby the fitness of the double 516 
resistance is higher than expected. Sign epistasis represents a particular interaction, 517 
whereby the sign of the fitness of a double mutant changes depending on genetic 518 
background – a single mutation may be deleterious on the susceptible background, but may 519 
be beneficial or have no effect on a single resistance background. (B) Epistasis between 520 
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resistances changes compensation. When double resistance is not epistatic, the prediction 521 
is that the same compensation targets as the sum of the ones found in the single resistances 522 
will be found. When double resistance interacts negatively, increasing the fitness cost, a new 523 
set of compensatory mutations targeting the negative epistasis can occur [72]. When double 524 
resistance interacts positively, reducing the fitness cost, less compensatory mutations are 525 
expected to be available than the sum of targets found in the single resistances. Thickness of 526 
orange arrows represents compensatory mutations of higher effect and the numbers 527 
represent an example of expected compensatory genes for each resistance. (C) Epistasis 528 
depends on the environment. Fitness of double resistance (Ant1
R + Ant2
R) depends on the 529 
environment. Not only the same single resistances to either antibiotic (Ant1
R, in green or 530 
Ant2
R, in red) may have a different fitness depending on the environment but also the 531 
interactions in between Ant1
R and Ant2
R mutations might change depending on the 532 
environment, leading to negative epistasis in the environment I (left panel) and positive 533 
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 Most antibiotic resistance mutations reduce bacterial fitness in the absence of the 847 
antibiotic, but some are not costly, or can even be advantageous in certain 848 
environments, including infection-related conditions. 849 
 Acquiring a new resistance can alleviate the cost of a pre-existing one, thus favouring 850 
the emergence of multidrug resistant bacteria. 851 
 The compensatory evolution of multidrug resistant bacteria is distinct from that of 852 
single-resistant bacteria, since the proteins mediating functional interactions 853 






Outstanding Questions 858 
 Fitness effects of AR are environmental dependent. How to identify the key 859 
characteristics of the environment to be able to predict resistance effects in vivo? 860 
 Compensation of costs of multiple resistances can occur in a few days in the lab. 861 
What is the rate at which compensation occurs in the human host?  862 
 How many mutations are adaptive to pathogens depending on the presence or 863 
absence of antibiotics in the environment? 864 
 To what extent is epistasis relevant in vivo and how to measure epistasis between 865 
many resistances? 866 
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